Ruling out pulmonary embolism across different healthcare settings: A systematic review and individual patient data meta-analysis
- PMID: 35077453
- PMCID: PMC8824365
- DOI: 10.1371/journal.pmed.1003905
Ruling out pulmonary embolism across different healthcare settings: A systematic review and individual patient data meta-analysis
Abstract
Background: The challenging clinical dilemma of detecting pulmonary embolism (PE) in suspected patients is encountered in a variety of healthcare settings. We hypothesized that the optimal diagnostic approach to detect these patients in terms of safety and efficiency depends on underlying PE prevalence, case mix, and physician experience, overall reflected by the type of setting where patients are initially assessed. The objective of this study was to assess the capability of ruling out PE by available diagnostic strategies across all possible settings.
Methods and findings: We performed a literature search (MEDLINE) followed by an individual patient data (IPD) meta-analysis (MA; 23 studies), including patients from self-referral emergency care (n = 12,612), primary healthcare clinics (n = 3,174), referred secondary care (n = 17,052), and hospitalized or nursing home patients (n = 2,410). Multilevel logistic regression was performed to evaluate diagnostic performance of the Wells and revised Geneva rules, both using fixed and adapted D-dimer thresholds to age or pretest probability (PTP), for the YEARS algorithm and for the Pulmonary Embolism Rule-out Criteria (PERC). All strategies were tested separately in each healthcare setting. Following studies done in this field, the primary diagnostic metrices estimated from the models were the "failure rate" of each strategy-i.e., the proportion of missed PE among patients categorized as "PE excluded" and "efficiency"-defined as the proportion of patients categorized as "PE excluded" among all patients. In self-referral emergency care, the PERC algorithm excludes PE in 21% of suspected patients at a failure rate of 1.12% (95% confidence interval [CI] 0.74 to 1.70), whereas this increases to 6.01% (4.09 to 8.75) in referred patients to secondary care at an efficiency of 10%. In patients from primary healthcare and those referred to secondary care, strategies adjusting D-dimer to PTP are the most efficient (range: 43% to 62%) at a failure rate ranging between 0.25% and 3.06%, with higher failure rates observed in patients referred to secondary care. For this latter setting, strategies adjusting D-dimer to age are associated with a lower failure rate ranging between 0.65% and 0.81%, yet are also less efficient (range: 33% and 35%). For all strategies, failure rates are highest in hospitalized or nursing home patients, ranging between 1.68% and 5.13%, at an efficiency ranging between 15% and 30%. The main limitation of the primary analyses was that the diagnostic performance of each strategy was compared in different sets of studies since the availability of items used in each diagnostic strategy differed across included studies; however, sensitivity analyses suggested that the findings were robust.
Conclusions: The capability of safely and efficiently ruling out PE of available diagnostic strategies differs for different healthcare settings. The findings of this IPD MA help in determining the optimum diagnostic strategies for ruling out PE per healthcare setting, balancing the trade-off between failure rate and efficiency of each strategy.
Conflict of interest statement
I have read the journal’s policy and the following authors of this manuscript have the following competing interests: FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, MSD, Daiichi-Sankyo, Actelion, the Dutch thrombosis association, The Netherlands Organisation for Health Research and Development and the Dutch Heart foundation. GLG holds the Chair on Diagnosis of Venous Thromboembolism from the Department of Medicine, University of Ottawa and a Clinician Scientist award from the Heart and Stroke Foundation of Canada. WG reports advisory board participation from Amgen, Novartis, Pfizer, Principia Biopharma Inc, a Sanofi Company, and Sanofi, SOBI, Griffols, UCB; lecture honoraria from Amgen, Novartis, and Pfizer; and grants from Bayer, Bristol Myers Squibb, SOBI, Griffols and Pfizer. No other disclosures were reported.
Figures



References
-
- Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al.. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. Epub 2019/09/11. doi: 10.1093/eurheartj/ehz405 . - DOI - PubMed
-
- den Exter PL, van Es J, Erkens PM, van Roosmalen MJ, van den Hoven P, Hovens MM, et al.. Impact of delay in clinical presentation on the diagnostic management and prognosis of patients with suspected pulmonary embolism. Am J Respir Crit Care Med. 2013;187(12):1369–73. Epub 2013/04/18. doi: 10.1164/rccm.201212-2219OC . - DOI - PubMed
-
- Hendriksen JM, Koster-van Ree M, Morgenstern MJ, Oudega R, Schutgens RE, Moons KG, et al.. Clinical characteristics associated with diagnostic delay of pulmonary embolism in primary care: a retrospective observational study. BMJ Open. 2017;7(3):e012789. Epub 2017/03/11. doi: 10.1136/bmjopen-2016-012789 ; PubMed Central PMCID: PMC5353317. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources